Abstract
Stem cells possess two basic characteristics: they are able to renew themselves and to develop into different cell types. The link between normal stem cells and tumor cells could be examined in three aspects: what are the differences and similarities in the control of self-renewal capacity between stem cells and tumor cells; whether tumor cells arise from stem cells; do tumorous stem cells exist? Since tumor cells also exhibit self-renewal capacity, it seems plausible that their regulation is similar to that of the stem cells. The infinite self-renewal ability (immortalization) is assured by several, so far only partly known, mechanisms. One of these is telomerase activity, another important regulatory step for survival is the inhibition of apoptosis. Other signal transduction pathways in stem cell regulation may also play certain roles in carcinogenesis: e.g. Notch, Sonic hedgehog (SHH), and Wnt signals. Existence of tumor stem cells was suggested since it is simpler to retain the self-renewal capacity than to reactivate the immortality program in an already differentiated cell. Moreover, stem cells live much longer than the differentiated ones, and so they are exposed for a long period of time to impairments, collecting gene errors leading to the breakdown of the regulation. However, it is still an open question whether all cells in the tumor possess the capacity that produces this tissue or not, that is: are there tumor stem cells or there are not. If tumor stem cells exist, they would be the main target for therapy: only these must be killed since the other tumor cells possess limited proliferative capacity, therefore limited life span. The only problem is that during tumor progression stem-like cells can develop continuously and the identification but mainly the prevention of their formation is still a great challenge.(Pathology Oncology Research Vol 10, No 2, 69–73)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thomson JA, Ilskovitz-Eldor M, Shapiro SS, et al: Embryonic stem cell lines derived from human blastocysts. Science 282: 1145–1147, 1998
Lagasse E, Connors H, Al-Dhalimy M, et al: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6: 1229–1234, 2000
Ferrari G, Cusella-De Angelis G, Coletta M, et al: Muscle regeneration by bone marrow-derived myogenic progenitor. Science 279: 1528–1530, 1998
Alison MR, Poulsom R, Jeffery R, et al: Hepatocytes from nonhepatic adult stem cells. Nature 406: 257, 2000
Eglitis MA, Mezey E: Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 94: 4080–4085, 1997
Orlic D, Kajsturo J, Chimenti S, et al: Bone marrow cells regenerate infarcted myocardium. Nature 410: 701–704, 2001
Poulsom R, Forbes SJ, Hodivala-Dilke K, et al: Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 195: 229–235, 2001
Preston SL, Alison MR, Forbes SJ, et al: The new stem cell biology: something for everyone. J Clin Pathol: Mol Pathol 56: 86–96, 2003
Trosko JE, Chang CC: Stem cell theory of carcinogenesis. Toxicol Lett 49: 283, 1989
Domen J, Gandy KL, Weissmann IL: Systemic overexpression of BCL2 in the hematopoetic system protects transgenic mice from the consequences of lethal irradiation. Blood 91: 2272–2282, 1998
Domen J, Weissman IL: Hematopoietic stem cellss need two signals to prevent apoptosis; BCL-2 can provide one of these, Kit/c-Kit signaling the other. J Exp Med 192: 1707–1718, 2000
Reya T, Morrison RJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105–111, 2001
Taipale J, Beachy PA: The Hedgehog and Wnt signaling pathways in cancer. Nature 411: 349–354, 2001
Varnum-Finney B, et al: Pluripotent, cytokine-dependent, hematopoetic stem cells are immortalized by constitutive Notch signaling. Nat Med 6: 1278–1281, 2000
Karanu FN, et al: The Notch ligand Jagged-1 represents a novel growth factor of human hematopoetic stem cells. J Exp Med 192: 1365–1372, 2000
Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature 414: 98–104, 2001
Dick JE. Self-renewal writ in blood. Nature, 423: 231, 2003
Lessard J, Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255–260, 2003
Gat U, DasGupta R, Deegenstein I, et al: De novo hair follicle morphogenesis and hair tumor sin mice expressing a truncated beta-catenin in skin. Cell 95: 605–614, 1998
Kojika S, Griffin JD: Notch receptors and hematopoiesis. Exp Hematol 29: 1041, 2001
Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch Signaling: Cell Fate Control and Signal Integration in Development. Science 284: 770–776, 1999
Hitoshi S, Alexson T, Tropepe V, Donoviel D et al. Notch pathway molecules are essential for the maintenance, but no the generation, of mammalian neural stem cells. Genes Dev 16: 846, 2002
Ingham PW:. Trancducing Hedgehog: the story so far. EMBO J 17: 3505, 1998
Bhardwaj G, Murdoch B, Wu D, Baker DP, et al: Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2: 172, 2001
Nowell PC: The clonal evolution of tumor cell population. Science 194: 23–28, 1976
Miyamoto T, Weissman IL, Akashi K: AML1/ETO expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 97: 7521–7526, 2000
Traver D, Akashi K, Weissman IL, Lagasse E: Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9: 47–57, 1998
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983–3988, 2003
Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci USA 100: 3547–3549, 2003